72P - Overcoming macrophage immunosuppression in small cell lung cancer with high-affinity sirpa variants

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Small-Cell Lung Cancer
Cancer Immunology and Immunotherapy
Translational Research
Presenter Kipp Weiskopf
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors K. Weiskopf1, P.J. Schnorr2, N. Jahchan2, A. Ring2, A. Volkmer2, J. Volkmer2, K.C. Garcia3, J. Sage2, I.L. Weissman2
  • 1Institute For Stem Cell Biology And Regenerative Medicine, Stanford University School of Medicine, 94305 - Stanford/US
  • 2Institute For Stem Cell Biology And Regenerative Medicine, Stanford University School of Medicine, Stanford/US
  • 3Molecular And Cellular Physiology, Stanford University School of Medicine, Stanford/US

Abstract

CD47 is a cell-surface molecule that allows cancer cells to evade the immune system by signaling through SIRPa, an inhibitory receptor on macrophages. Therapies that block CD47 stimulate macrophage phagocytosis and destruction of cancer cells. Here, we hypothesized that CD47-blocking therapies could be used as effective treatments for small cell lung cancer (SCLC) in preclinical models. We aimed to identify new tumor antigens on SCLC cells and target them in combination with CD47-blocking therapies.